newest glp 1 drug Eli Lilly to seek approval of new GLP-1 weight-loss this year GLP-1 Drugs Cut Risk of

www.fda.gov/Drugs/DrugSafety/ 18

Recent Developments: 2025: Eli Lilly received FDA approval for tirzepatide (Zepbound) as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity the first pharmacotherapy approved for this indication expanding tirzepatide's approved uses beyond metabolic conditions into a respiratory indication affecting over 30 million Americans and supported by SURMOUNT-OSA trial data showing 63% reduction in apnea-hypopnea index

At the same time, the industry is already shifting toward next-generation incretin therapies focused on improving efficacy, tolerability and convenience

When it comes to clinical manufacturing, research-grade standards that are good for early finding are no longer enough

SGLT-2 inhibitors: the gap seems to be leveling off

Liraglutide was shown to prevent synapse loss and deterioration of synapse plasticity in the hippocampus of APP/PS1 mice, while enhance synaptic plasticity in the control mice (158, 175)